Knowledge support for environmental information on pharmaceuticals: experiences among Swedish Drug and Therapeutics Committees.

Drug and Therapeutics Committees Environment Knowledge support Pharmaceuticals Recommended medicines Survey

Journal

BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677

Informations de publication

Date de publication:
12 Jun 2023
Historique:
received: 02 01 2023
accepted: 05 06 2023
medline: 14 6 2023
pubmed: 13 6 2023
entrez: 12 6 2023
Statut: epublish

Résumé

Two publicly available Swedish knowledge support systems, "Pharmaceuticals and Environment" on Janusinfo.se and Fass.se, provide environmental information on pharmaceuticals. Janusinfo is provided by the public healthcare system in Stockholm and Fass is provided by the pharmaceutical industry. The objectives of this study were to investigate the experiences among Swedish Drug and Therapeutics Committees (DTCs) with using the databases, retrieve development proposals for these, and investigate the DTCs' challenges with working with pharmaceuticals in the environment. A cross-sectional survey with 21 questions, both closed and open-ended, was distributed electronically in March 2022 to Sweden's 21 DTCs. Descriptive statistics and inductive categorization were used for the analysis. A total of 132 respondents from 18 regions filled out the survey. The average regional response rate was 42%. The DTCs used the knowledge supports to consider environmental aspects of pharmaceuticals in their formularies and in education. Respondents were more familiar with Janusinfo compared to Fass but appreciated the availability of both. The DTCs especially valued the concrete proposals for certain active pharmaceutical ingredients on Janusinfo. Respondents requested that all medicinal products have environmental information on Fass. Challenges included lack of data, lack of transparency from the pharmaceutical industry and difficulties considering the environmental aspect of pharmaceuticals in their healthcare practice. Respondents wanted more knowledge, clear messages, and legislation to support their work to reduce the negative environmental impact of pharmaceuticals. This study demonstrates that knowledge supports for environmental information on pharmaceuticals are valuable for the DTCs in Sweden, but the respondents experienced challenges in their work in this field. The study can provide insights to those in other countries interested in considering environmental aspects in their formulary decision-making.

Sections du résumé

BACKGROUND BACKGROUND
Two publicly available Swedish knowledge support systems, "Pharmaceuticals and Environment" on Janusinfo.se and Fass.se, provide environmental information on pharmaceuticals. Janusinfo is provided by the public healthcare system in Stockholm and Fass is provided by the pharmaceutical industry. The objectives of this study were to investigate the experiences among Swedish Drug and Therapeutics Committees (DTCs) with using the databases, retrieve development proposals for these, and investigate the DTCs' challenges with working with pharmaceuticals in the environment.
METHODS METHODS
A cross-sectional survey with 21 questions, both closed and open-ended, was distributed electronically in March 2022 to Sweden's 21 DTCs. Descriptive statistics and inductive categorization were used for the analysis.
RESULTS RESULTS
A total of 132 respondents from 18 regions filled out the survey. The average regional response rate was 42%. The DTCs used the knowledge supports to consider environmental aspects of pharmaceuticals in their formularies and in education. Respondents were more familiar with Janusinfo compared to Fass but appreciated the availability of both. The DTCs especially valued the concrete proposals for certain active pharmaceutical ingredients on Janusinfo. Respondents requested that all medicinal products have environmental information on Fass. Challenges included lack of data, lack of transparency from the pharmaceutical industry and difficulties considering the environmental aspect of pharmaceuticals in their healthcare practice. Respondents wanted more knowledge, clear messages, and legislation to support their work to reduce the negative environmental impact of pharmaceuticals.
CONCLUSIONS CONCLUSIONS
This study demonstrates that knowledge supports for environmental information on pharmaceuticals are valuable for the DTCs in Sweden, but the respondents experienced challenges in their work in this field. The study can provide insights to those in other countries interested in considering environmental aspects in their formulary decision-making.

Identifiants

pubmed: 37309002
doi: 10.1186/s12913-023-09646-7
pii: 10.1186/s12913-023-09646-7
pmc: PMC10259041
doi:

Substances chimiques

Ditiocarb 99Z2744345
Pharmaceutical Preparations 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

618

Informations de copyright

© 2023. The Author(s).

Références

Environ Sci Technol. 2020 Apr 7;54(7):4110-4120
pubmed: 32208629
Proc Natl Acad Sci U S A. 2022 Feb 22;119(8):
pubmed: 35165193
J Clin Nurs. 2007 Feb;16(2):234-43
pubmed: 17239058
Br J Clin Pharmacol. 2020 Jan;86(1):10-12
pubmed: 31625180
Expert Rev Pharmacoecon Outcomes Res. 2009 Feb;9(1):65-83
pubmed: 19371180
BMJ Open. 2017 May 2;7(4):e014345
pubmed: 28465306
Environ Toxicol Chem. 2022 Jun 30;:
pubmed: 35770719
Curr Environ Health Rep. 2016 Jun;3(2):153-60
pubmed: 27068434
J Hazard Mater. 2007 Sep 30;148(3):751-5
pubmed: 17706342
Eur J Clin Pharmacol. 2020 Aug;76(8):1151-1160
pubmed: 32388641
Environ Toxicol Chem. 2016 Apr;35(4):823-35
pubmed: 26666847
Sci Total Environ. 2010 May 1;408(11):2327-39
pubmed: 20206966
Eur J Clin Pharmacol. 2018 Jan;74(1):131-138
pubmed: 29063149
Regul Toxicol Pharmacol. 2020 Mar;111:104571
pubmed: 31893528
Eur J Clin Pharmacol. 2013 May;69 Suppl 1:79-87
pubmed: 23640192
Br J Clin Pharmacol. 2022 Dec;88(12):5074-5082
pubmed: 36000992
Bull World Health Organ. 2021 Apr 1;99(4):319-320
pubmed: 33953450

Auteurs

Elkanah Linder (E)

Pharmacoepidemiology & Social Pharmacy, Department of Pharmacy, Uppsala University, Uppsala, Sweden. elkanah.linder@farmaci.uu.se.

Björn Wettermark (B)

Pharmacoepidemiology, Department of Pharmacy, Uppsala University, Uppsala, Sweden.

Marie-Louise Ovesjö (ML)

Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Department of Quality and Patient safety, Södersjukhuset, Stockholm, Sweden.

Sofia Kälvemark Sporrong (SK)

Social Pharmacy, Department of Pharmacy, Uppsala University, Uppsala, Sweden.

Helena Ramström (H)

Health and Medical Care Administration, Region Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH